Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2024 — March 6, 2024 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors https://dailynews.ascopubs.org/do/destiny-pantumor-02-trastuzumab-deruxtecan-has-activity-against-range-her2-expressing

LBA34 - Trastuzumab Deruxtecan (T-DXd) for Pretreated Patients (pts) With HER2-Expressing Solid Tumors: Primary Analysis From the DESTINY-PanTumor02 (DP-02) Study https://oncologypro.esmo.org/meeting-resources/esmo-congress/trastuzumab-deruxtecan-t-dxd-for-pretreated-patients-pts-with-her2-expressing-solid-tumors-primary-analysis-from-the-destiny-pantumor02-dp-02

Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730032/

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial https://pubmed.ncbi.nlm.nih.gov/36977309/

A Study of DB-1303 in Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/study/NCT05150691

DNA Mismatch Repair Proteins: Scientific Update and Practical Guide https://pubmed.ncbi.nlm.nih.gov/33597222/

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) https://clinicaltrials.gov/study/NCT04209855

PRO1184 for Advanced Solid Tumors (PRO1184-001) https://www.clinicaltrials.gov/study/NCT05579366

A New Wave of Innovations Within the DNA Damage Response https://pubmed.ncbi.nlm.nih.gov/37679326/

Center for DNA Damage and Repair https://www.dana-farber.org/research/integrative-research/dna-damage-and-repair

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions https://pubmed.ncbi.nlm.nih.gov/33806979/

Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile https://pubmed.ncbi.nlm.nih.gov/35365770/

The Emerging Genomic Landscape of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/24170611/

Drs Ursula A. Matulonis and Alexi A. Wright discuss survivorship issues in endometrial cancer including sexual dysfunction, mental health, fatigue, and peripheral neuropathy.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999849. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Cancer Survivorship Guidelines https://emedicine.medscape.com/article/2500027-overview

Patterns and Predictors of Cancer-Related Fatigue in Ovarian and Endometrial Cancers: 1-Year Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/32436610/

Research Status of Internet-Delivered Cognitive Behavioral Therapy in Cancer Patients https://pubmed.ncbi.nlm.nih.gov/38073902/

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/28253393/

Pilot Randomized Trial of an Acceptance-Based Telehealth Intervention for Women With Ovarian Cancer and PARP Inhibitor-Related Fatigue https://pubmed.ncbi.nlm.nih.gov/37708581/

Improvements Following Multimodal Pelvic Floor Physical Therapy in Gynecological Cancer Survivors Suffering From Pain During Sexual Intercourse: Results From a One-Year Follow-Up Mixed-Method Study https://pubmed.ncbi.nlm.nih.gov/35077479/

Mismatch Repair Deficiency and Clinicopathological Characteristics in Endometrial Carcinoma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33845554/

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life https://pubmed.ncbi.nlm.nih.gov/34292766/

Enhanced Recovery After Surgery (ERAS): A Perspective Review of Postoperative Pain Management Under ERAS Pathways and Its Role on Opioid Crisis in the United States https://pubmed.ncbi.nlm.nih.gov/31868759/

Drs Ursula A. Matulonis and Joyce F. Liu discuss new therapeutics for patients with endometrial cancer, including ADCs, immunotherapy, and drugs targeting replication stress.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999850. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36291804/

Uterine Cancer https://emedicine.medscape.com/article/258148-overview

Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability https://pubmed.ncbi.nlm.nih.gov/33182707/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

PDUFA VII: Fiscal Years 2023-2027 https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-fiscal-years-2023-2027

NCCN Drugs & Biologics Compendium https://www.nccn.org/docs/default-source/clinical/drugs-and-biologics-compendium-user-guide.pdf

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/37627113/

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu https://pubmed.ncbi.nlm.nih.gov/29584549/

Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma https://clinicaltrials.gov/study/NCT05256225

HER2 Amplification in p53-Mutated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/36900227/

Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/33335423/

Application of NGS Molecular Classification in the Diagnosis of Endometrial Carcinoma: A Supplement to Traditional Pathological Diagnosis https://pubmed.ncbi.nlm.nih.gov/36341543/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

The Role of Immunotherapy in Advanced and Recurrent MMR Deficient and Proficient Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/36493574/

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/

Phase 3, Randomized, Open-Label Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Cancer: ENGOT-en9/LEAP-001 https://pubmed.ncbi.nlm.nih.gov/34799418/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

FDA Grants Accelerated Approval to Fam-trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2